Cargando…
Systemic vs. Topical Therapy for the Treatment of Vulvovaginal Candidiasis
It is estimated that 75% of all women will experience at least 1 episode of vulvovaginal candidiasis (VVC) during their lifetimes. Most patients with acute VVC can be treated with short-term regimens that optimize compliance. Since current topical and oral antifungals have shown comparably high effi...
Autor principal: | Faro, Sebastian |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364342/ https://www.ncbi.nlm.nih.gov/pubmed/18475346 http://dx.doi.org/10.1155/S1064744994000098 |
Ejemplares similares
-
New Treatments for Vulvovaginal Candidiasis
por: Faro, Sebastian
Publicado: (1996) -
Topical Treatment of Recurrent Vulvovaginal Candidiasis: An Expert Consensus
por: Phillips, Nancy A., et al.
Publicado: (2022) -
New Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis
por: Pérez-González, Noelia, et al.
Publicado: (2021) -
Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis
por: Ge, Gai, et al.
Publicado: (2022) -
Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
por: Grant, Leah M., et al.
Publicado: (2022)